Status:
COMPLETED
Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients
Lead Sponsor:
Saint Luke's Health System
Collaborating Sponsors:
Amylin Pharmaceuticals, LLC.
Conditions:
Hyperglycemia
Acute Coronary Syndromes
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine the efficacy of intravenous Exenatide therapy in hyperglycemic patients admitted to the coronary intensive care unit.
Detailed Description
Diabetic patients with acute myocardial infarction (MI) have particularly poor outcomes. Clinical practice guidelines from the American College of Cardiology/American Heart Association for the treatme...
Eligibility Criteria
Inclusion
- Admission to coronary ICU
- Admission blood glucose 140-299 mg/dL
- Primary cardiovascular diagnosis by attending physician
- Under primary care of cardiology service
- Age \> 18 years old
- Ventilator independent
- Able to provide informed consent
Exclusion
- Admission blood glucose \< 140 or \> 300 mg/dL
- Ventilator dependent
- Unconscious sedation
- Type 1 diabetes
- Known pregnancy
- Admitted to coronary ICU for right heart cath to measure hemodynamics prior to transplant
- Post transplant procedure
- Currently enrolled in another clinical trial
- Unable to provide informed consent
- Creatinine clearance \< 30 mL/min
- On insulin treatment except for monotherapy with long-acting basal insulin (e.g., insulin glargine \[Lantus®\] or detemir \[Levemir®\])
- Gastroparesis
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00736229
Start Date
August 1 2008
End Date
August 1 2012
Last Update
November 20 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mid America Heart Institute Saint Luke's Health System
Kansas City, Missouri, United States, 64111